In early BC, PIK3CA mutations have been detected in 37%, 22% and 18% of ER + /HER2-, HER2 + and ER-/HER2- subtypes, respectively and associated with improved invasive disease-free survival but also with resistance to HER2-targeted treatments [3, 5]. This evidence concerns the gene PIK3CA and breast cancer.